Update on InnomarClinics
InnomarClinics remain open to our patients amidst coronavirus (COVID-19) concerns.
Learn more.

Canadian Regulatory Intelligence and Foreign Safety Updates

Healthcare companies must stay informed of changes to regulations, guidances, policies, and regulatory information for pharmaceuticals and medical devices. This requires monitoring multiple websites and changes that are introduced. However, even the most efficient associate will spend hours each week trying to find, review, and compile all of this information.

Get a Canadian Regulatory Intelligence Update Delivered to Your Inbox Every Week

The Canadian Regulatory Intelligence Update, published by TPIreg™, the regulatory division of Innomar Strategies, provides the following updates on a weekly basis: 

All updates related to drugs and devices from Health Canada, issued through the 

  • Biologic and Radiopharmaceutical Drugs Directorate (BRDD),
  • Therapeutic Products Directorate (TPD),
  • Marketed Health Products Directorate (MHPD),
  • Medical Devices Directorate (MDD),
  • Non-prescription and Natural Health Products Directorate (NNHPD) and
  • Drug Establishment Licencing (DEL) updates

Plus

  • All updates issued from the Canadian Agency for Drugs and Technologies in Health (CADTH)
  • All updates issued from Patented Medicine Prices Review Board (PMPRB)
  • All updates issued from Pharmaceutical Advertising Advisory Board (PAAB)
  • All updates issued from Canadian Environmental Protection Agency (CEPA) related to drugs

Monitor Foreign Safety Updates

Health Canada also requires the submission of foreign safety updates. In addition to our regulatory intelligence publication, our weekly Foreign Authorities Safety Update provides updates, including recalls and safety notices, from the countries that Health Canada is expecting you to monitor, including the U.S., Switzerland, France, and many more. The information provided is collected from all countries that have a searchable database and is aggregated by generic name.

Any company can easily verify if a drug they sell is covered and determine if there is a need to alert Health Canada within the prescribed 72-hour period.

Free Trial: Get a Complimentary Subscription Until January 2020

For the remainder of 2020, new subscribers can receive a free trial of these publications, regularly priced at $2000.00 CDN each on an annual basis.

Following December 31st, 2020, subscribers have the following renewal options:

  1. Renew either one of the publications for $2000.00 annually – less than $50.00 per week
  2. Renew both publications for $3000.00 annually – a savings of 25% at less than $75.00 per week